Peking University First Hospital
Beijing, Beijing Municipality, 100871, China
NCT Number: NCT06156280
This project is divided into a single dose escalation and a multiple dose escalation phase Ia clinical study. This is a single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQH2929 injection in healthy adults.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Beijing, Beijing Municipality, 100871, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
Placebo comparator
Time frame: Single dose: Up to Day 113
The occurrence of all adverse events (AE).
Time frame: Single dose: Up to Day 113
The occurrence of all adverse events (SAE).
Time frame: Single dose: Up to Day 113
The occurrence of all treatment-related adverse events (TRAE).
Time frame: Single administration dose (SAD) group: up to Day 113
Proportion of subjects with clinical laboratory abnormalities
Time frame: 1 hour pre-dose, 0, 0.5, 1, 2, 6, 12, 24, 48, 72, 168, 336, 504, 672, 840, 1008, 1344, 1680, 2016, 2353, 2688 hours postdose.
Time to reach maximum (peak) serum concentration after administration in SAD group
Time frame: 1 hour pre-dose, 0, 0.5, 1, 2, 6, 12, 24, 48, 72, 168, 336, 504, 672, 840, 1008, 1344, 1680, 2016, 2353, 2688 hours postdose.
The maximum observed serum concentration of study drug in SAD group.
Time frame: 1 hour pre-dose, 0, 0.5, 1, 2, 6, 12, 24, 48, 72, 168, 336, 504, 672, 840, 1008, 1344, 1680, 2016, 2353, 2688 hours postdose.
Area under the concentration-time curve of the TQH2929 Injection in serum over the time interval from 0 extrapolated to infinity in SAD group.
Time frame: 1 hour pre-dose, 0, 0.5, 1, 2, 6, 12, 24, 48, 72, 168, 336, 504, 672, 840, 1008, 1344, 1680, 2016, 2353, 2688 hours postdose.
Area under the concentration-time curve of the TQH2929 Injection in serum over the time interval from 0 extrapolated to the last quantifiable data time-point in SAD group.
Time frame: 1 hour pre-dose, 0, 0.5, 1, 2, 6, 12, 24, 48, 72, 168, 336, 504, 672, 840, 1008, 1344, 1680, 2016, 2353, 2688 hours postdose.
Apparent volume of distribution of the TQH2929 Injection in serum in SAD group.
Time frame: 1 hour pre-dose, 0, 0.5, 1, 2, 6, 12, 24, 48, 72, 168, 336, 504, 672, 840, 1008, 1344, 1680, 2016, 2353, 2688 hours postdose.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body, in SAD group.
Time frame: 1 hour pre-dose, 0, 0.5, 1, 2, 6, 12, 24, 48, 72, 168, 336, 504, 672, 840, 1008, 1344, 1680, 2016, 2353, 2688 hours postdose.
The time required for half of the drug to be eliminated from the serum in SAD group.
Time frame: SAD group: 1 hour pre-dose, postdose on Day 15, Day 57, Day 85, Day 113.
Proportion of subjects with a positive ADA reading at any time point during the study.
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Industry
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Efficacy of TQH2929 in Healthy Adult Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04728165
Psoriasis, Skin Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT01778569
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT05295979
Psoriasis, Skin Diseases
Hong Kong
View Trial DetailsNCT07712731
Psoriasis, Skin Diseases
Baotou, China
View Trial Details